Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate original principal amount of $1,384,615.39 (effective 2023-02-17).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- certain investors
- Value
- aggregate original principal amount of $1,384,615.39
- Effective
- 2023-02-17
Exact text from the filing
On February 17, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company” ), entered into a securities purchase agreement (“ SPA” ), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,384,615.39 (the “ Notes” ) and warrants (“ Warrants” ) to purchase an aggregate 69,230,769 shares of common stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering” ). The Offering closed on February 17, 2023 (the “ Closing Date” ) and as a result, the Company issued an aggregate $1,384,615.39 in the aggregate principal amount of Notes and Warrants to purchase 69,230,769 shares of Common Stock.
View on SEC.gov